Rosetta Genomics said this week that it has signed an exclusive marketing deal under which tort claims administration firm PACE Claims Services will provide information about Rosetta's mesothelioma diagnostic test to defendants and insurers in mesothelioma legal cases.
The single largest risk factor for developing mesothelioma is exposure to asbestos, according to Rosetta. Rosetta's miRview Meso is designed to differentiate lung cancer from mesothelioma.
"With mesothelioma on the rise outside the US, and new cases of this cancer coming to light on a regular basis, mesothelioma litigation has become a multi-billion dollar industry in compensation claims against manufacturers of asbestos, as well as the companies that allegedly exposed staff to this substance without adequate protection and warning,” Bradley Drew, managing director of PACE, said in a statement. “As a result, it is increasingly important to determine with certainty whether a carcinoma is mesothelioma or a different carcinoma of the lung or pleura.”
The deal with PACE represents an expansion of Rosetta's ongoing efforts to market its miRview line of microRNA-based diagnostics, the company said.
Previously, Prometheus Laboratories had been the exclusive marketer of the tests in the US. However, that arrangement was terminated in late 2010 after a dispute over how the tests were commercialized (GSN 12/2/2010).
Earlier this year, Rosetta launched its own US sales team to handle the marketing of the diagnostics (GSN 5/5/2011).